Proteomics

Dataset Information

0

Comparative analysis of commercial human primary mesangial cell, implications for experimental design.

ABSTRACT: Research on human glomerular mesangial cells (MCs) is mainly performed in vitro on primary MCs. Commercially available MCs originate from different donors and thus, because of their origin, the outcome of the experiments could potentially be affected. We have compared two commercially available primary human MCs (HMCv1 and HMCv2) using proteomics. Baseline differences and differences after treatment with a known proliferation factor (PDGF-B) were investigated.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Primary Cell, Glomerular Mesangial Cell

SUBMITTER: Evelin Berger  

LAB HEAD: Carina Sihlbom Wallem

PROVIDER: PXD060148 | Pride | 2025-10-06

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
4659_SPhuman_TMTpro_0mc_CarbC_Eclipse_230504_FAIMS_12-41.msf Msf
4659_SPhuman_TMTpro_0mc_CarbC_Eclipse_230504_FAIMS_12-41.pdResult Other
4659_SPhuman_TMTpro_0mc_CarbC_Eclipse_230504_FAIMS_12-41_5proFDRproteins_SENT.xlsx Xlsx
Eclipse_230504_FAIMS_12.raw Raw
Eclipse_230504_FAIMS_13.raw Raw
Items per page:
1 - 5 of 34
altmetric image

Publications

Comparative analysis of commercial human primary mesangial cell, implications for experimental design.

Johansson Alva A   Narasimhan Gayathri G   Keuenhof Katharina K   Boi Roberto R   Ebefors Kerstin K  

BMC nephrology 20250929 1

<h4>Background</h4>Mesangial cells (MCs) are involved in several glomerular diseases such as IgA nephropathy and diabetic kidney disease. In vitro work on human MCs is mainly conducted on primary MCs. However, cells from different donors could be significantly different, thus potentially affecting the outcome of the experiments.<h4>Method</h4>We have compared commercially available primary human MCs from two different sources: HMCv1 and HMCv2. The cells were characterized using qPCR, western blo  ...[more]

Similar Datasets

Transcriptomics DNA methylation in marmoset primed and naive pluripotent stem cells, and trophoblast stem cells
2024-11-21 | E-MTAB-12453 | biostudies-arrayexpress
Genomics Low pass whole methylome enzymatic sequencing of 11 T-ALL cell lines untreated and after treatment with different concentrations of 5-azacytidine (AZA), 5-aza-2′-deoxycytidine (DEC) and GSK3685032 (GSK5032) for 3 and 7 days
2024-10-13 | E-MTAB-14197 | biostudies-arrayexpress
Genomics Low pass whole methylome enzymatic sequencing of four AML cell lines untreated and after treatment with different concentrations of 5-azacytidine (AZA), 5-aza-2′-deoxycytidine (DEC), Cytarabine (ARAC) and GSK3685032 (GSK5032) for 3 and 7 days
2025-04-10 | E-MTAB-14969 | biostudies-arrayexpress
Transcriptomics Benchmarking brain organoid recapitulation of fetal corticogenesis
2022-12-31 | E-MTAB-11239 | biostudies-arrayexpress
Transcriptomics Human iPSC-derived cardiomyocytes of peripartum cardiomyopathy patients reveal aberrant expression of sterol and lipid metabolism pathways
2020-12-08 | E-MTAB-9053 | biostudies-arrayexpress
Genomics ChIP-seq O-GlcNac in mouse ES cells
2024-08-31 | E-MTAB-14310 | biostudies-arrayexpress
Transcriptomics RNA-seq of the human acute myeloid leukemia cell line MOLM-13 treated with the METTL3 inhibitor UZH2 for 16 h compared to untreated controls
2022-10-01 | E-MTAB-11952 | biostudies-arrayexpress
Transcriptomics CutnRun of O-GlcNac in mouse ES cells in high glucose condition
2024-08-31 | E-MTAB-14308 | biostudies-arrayexpress
Transcriptomics CutnRun of O-GlcNac in mouse ES cells in low glucose condition at 6 hours, 8 hours, and 1 week
2024-08-31 | E-MTAB-14309 | biostudies-arrayexpress
Proteomics Suppression of the E. coli rnpA49 conditionally lethal phenotype via different compensatory mutations
2024-05-15 | PXD047498 | Pride